TESSA® AAV Production Technology For Scalable High-Quality Manufacturing

A next‑generation AAV manufacturing platform offers a streamlined, scalable solution for producing high‑quality vectors without the constraints of plasmid‑based systems. Built on a self‑silencing adenoviral backbone, this approach eliminates transfection‑related variability and enables up to 30‑fold higher yields across diverse serotypes. Programs benefit from improved efficiency, reduced cost of goods, and a simplified supply chain, allowing earlier adoption of commercial‑ready processes.

The system generates up to 80% full capsids before enrichment—significantly reducing downstream purification demands—and produces drug substance with no detectable helper virus, supporting stronger safety and regulatory confidence. Demonstrated scalability reaches 200L with a clear path to 2,000L and beyond, supported by bioreactor‑based suspension platforms designed for consistent batch‑to‑batch performance. Two configurations accommodate different development priorities: one optimized for speed and another for customization. Altogether, this platform sets a new standard in AAV manufacturing by uniting yield, purity, and scalability in a commercially aligned framework.